版本:
中国

BRIEF-Revive Therapeutics provides corporate update

March 29 Revive Therapeutics Ltd

* Revive Therapeutics provides corporate update

* Says has engaged with five clinical sites to advance phase 2 study of revenue-004 (bucillamine) in cystinuria Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐